IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

MDL 2724 16-MD-2724 HON. CYNTHIA M. RUFE

THIS DOCUMENT RELATES TO:

ALL ACTIONS

PURCHASING DEFENDANTS' OBJECTIONS TO SPECIAL MASTER DAVID H. MARION'S ELEVENTH REPORT AND RECOMMENDATION

AmerisourceBergen Drug Corp., H.D. Smith, LLC, Cardinal Health, Inc., The Harvard Drug Group, LLC, McKesson Corp., Morris & Dickson, Co., LLC, Red Oak Sourcing, LLC, and Walgreens Boots Alliance, Inc. (collectively, the "Purchasing Defendants"), in accordance with Pretrial Order No. 163 (ECF Doc. No. 1707) and Fed. R. Civ. P. 53(f), submit these objections to Special Master David H. Marion's Eleventh Report and Recommendation (the "11th R&R") (ECF Doc. No. 1983).

The 11th R&R, issued on March 6, 2022, recommends a schedule to govern the nonbellwether cases in this MDL, including, in relevant part, a recommendation "that all Defendants be required to file Answers to the Complaints, including affirmative defenses, within thirty (30) days of the date of acceptance of this Recommendation, or the Court's ruling thereon," id. ¶ II.2, and a recommendation that "discovery in all cases should proceed now on parallel tracks," id. ¶ II.3. The 11th R&R would create a significant burden if applied to the Purchasing Defendants, who have pending motions to dismiss the only complaint against them and therefore who have never answered any complaints in these cases, and who have a negotiated, court-approved stay of party discovery until that motion is resolved. Accordingly, after publication of the 11th R&R, counsel for McKesson Corp. wrote to Special Master Marion seeking clarification that Paragraphs II.2 and II.3 of the 11th R&R were not meant to apply to the Purchasing Defendants. In response, Special Master Marion confirmed that the 11th R&R "was entered without any consideration" of the Purchasing Defendants' "special circumstances," which "were not presented or considered in the briefing or conference calls preceding the 11th R&R."2 That is correct, as counsel to the Purchasing Defendants were not even aware of any of the proposals submitted to Special Master

¹ See March 9 Letter from A. Ellis to D. Marion, attached hereto as Exhibit A.

² March 9 E-mail from D. Marion to A. Ellis, attached hereto as Exhibit B.

Marion in connection with the 11th R&R and thus did not participate at all. The Special Master declined to provide the requested clarification, however, and suggested that McKesson "use the objection process" to raise its concerns with the Court.³

I. The Purchasing Defendants Should Not Be Required to Answer the IRPs' Complaint While Their Motion to Dismiss Is Pending

The Purchasing Defendants are uniquely situated in this litigation because they are named as defendants in only a single complaint⁴—the complaint filed by the Indirect Reseller Plaintiffs ("IRPs") in December 2019 (No. 19-cv-6044, ECF Doc. No. 1)⁵—and because many of them are absent class members of the many complaints filed by the Direct Purchaser Plaintiffs. The Purchasing Defendants moved to dismiss the IRPs' complaint in July 2020 and therefore have never answered any complaint. Filing and serving an answer under those circumstances would impose a significant burden on the Purchasing Defendants and run contrary to both the letter and spirit of the Federal Rules of Civil Procedure.⁶ Additionally, the IRPs have confirmed to the Purchasing Defendants that they are not seeking answers from the Purchasing Defendants at this time. With the only affected parties in agreement on this point, the Purchasing Defendants respectfully request that the Court modify Paragraph II.2 of the 11th R&R to exclude the Purchasing Defendants from the requirement that they answer the IRPs' complaint.

³ *Id*.

⁴ McKesson was previously named as a defendant in a suit brought by Marion Diagnostic Center, LLC and Marion Healthcare, LLC, but obtained a complete dismissal of that complaint in an order from the Court dated June 26, 2019. (No. 18-cv-4137, ECF Doc. No. 112).

⁵ The IRPs subsequently amended their complaint in May 2020. (No. 19-cv-6044, ECF Doc. No. 61).

⁶ See Fed. R. Civ. P. 12(a)(4)(A) ("[I]f the court denies the motion . . . the responsive pleading must be served within 14 days after notice of the court's action.").

II. The Purchasing Defendants' Stay of Party Discovery Should Remain in Effect

The Purchasing Defendants are also subject to a carefully negotiated and Court-ordered stay of party discovery. Specifically, in April 2020, the Court approved a stipulation between the IRPs and the Purchasing Defendants ordering that "all party discovery [as to the Purchasing Defendants] is stayed" and that the Purchasing Defendants "shall not be required to produce any documents in response to IRP RFPs during the pendency of the [Purchasing Defendants'] Motions to Dismiss." (No. 19-cv-6044, ECF Doc. No. 40) ("Stay Order"). Absent modification, Special Master Marion's recommendation that "discovery in all cases should proceed now on parallel tracks" would directly contradict that Stay Order. There is no justification for doing so. While the Court has allowed party discovery to proceed against manufacturers who still have Rule 12 motions pending, it has already determined that there are sufficient allegations in the plaintiffs' complaints to state a claim for conspiracy among the generic manufacturers. No conspiracy claims have been sustained against any of the Purchasing Defendants and none of the conspiracy claims that have withstood a Rule 12 motion have involved the alleged participation of any of the Purchasing Defendants. Further, the IRPs have confirmed that they have not sought, and still do not seek, to alter the status quo as set out in the Stay Order. With the parties in agreement on this point as well, the Purchasing Defendants respectfully request that the Court modify Paragraph II.3 of the 11th R&R to exclude the Purchasing Defendants pending resolution of the Purchasing Defendants' motions to dismiss.

Dated: March 27, 2022

Respectfully submitted,

<u>/s/ Abram J. Ellis</u> On behalf of Purchasing Defendants

Counsel for McKesson Corporation	Counsel for AmerisourceBergen Drug Corp. and H.D.
/s/ Abram J. Ellis	Smith, LLC
(D.C. Bar # 497634)	/s/ Michelle A. Mantine (w/consent)
Abram J. Ellis	(PA Bar # 203102)
Sara Y. Razi	Michelle A. Mantine
Joshua G. Hazan	Christopher R. Brennan
SIMPSON THACHER & BARTLETT LLP	Courtney B. Averbach
900 G Street NW	Danielle L. Stewart
Washington, DC 20001	REED SMITH LLP
202-636-5579	225 Fifth Avenue
aellis@stblaw.com	Pittsburgh, PA 15222
sara.razi@stblaw.com	412-288-4268/4583
joshua.hazan@stblaw.com	mmantine@reedsmith.com
	cbrennan@reedsmith.com
	caverbach@reedsmith.com
	dstewart@reedsmith.com
Counsel for Cardinal Health, Inc. and The Harvard	Counsel for Walgreens Boots Alliance, Inc.
Drug Group, LLC	/s/ Brian Byrne (w/consent)
/s/ Jason C. Murray (w/consent)	(D.C. Bar # 449881)
(CA Bar # 169806)	Brian Byrne
Jason C. Murray	Steven J. Kaiser
Katie Yablonka	Carl Lawrence Malm
Jordan Ludwig	CLEARY GOTTLIEB STEEN & HAMILTON LLP
CROWELL & MORING LLP	2112 Pennsylvania Avenue NW, Suite 1000
515 South Flower Street, 40th Floor	Washington, DC 20037
Los Angeles, CA 90071	202-974-1500
213-443-5590	bbyrne@cgsh.com
jmurray@crowell.com	
intarray (a) crowen.com	skaiser(a)cgsh.com
	skaiser@cgsh.com lmalm@cgsh.com
kyablonka@crowell.com jludwig@crowell.com	© ©

Counsel for Red Oak Sourcing, LLC

/s/ John F. Zabriskie (w/consent)

(IL Bar # 6187887) John F. Zabriskie Benjamin R. Dryden

FOLEY & LARDNER LLP

321 N. Clark Street, Suite 3000

Chicago, IL 60654 312-832-5199 izabriskie@folev.co

jzabriskie@foley.com bdryden@foley.com Counsel for Morris & Dickson Co., LLC

/s/ Barry Barnett (w/consent)

(TX Bar # 01778700)

Barry Barnett

Thomas W. Paterson

Drew Hansen

SUSMAN GODFREY LLP

8115 Preston Road, Suite 575

Dallas, Texas 75225

866-754-1900

bbarnett@susmangodfrey.com tpaterson@susmangodfrey.com dhansen@susmangodfrey.com